ZURA Key Statistics, Chart & Performance
The current stock price of ZURA is 6.01 USD. In the past month the price increased by 14.26%. In the past year, price increased by 262.05%.
ZURA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ZURA. When comparing the yearly performance of all stocks, ZURA is one of the better performing stocks in the market, outperforming 98.66% of all stocks.
ZURA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZURA. While ZURA has a great health rating, there are worries on its profitability.
ZURA Financial Highlights
Over the last trailing twelve months ZURA reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS decreased by -4.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.44% | ||
| ROE | -57.76% | ||
| Debt/Equity | 0 |
ZURA Forecast & Estimates
13 analysts have analysed ZURA and the average price target is 16.32 USD. This implies a price increase of 171.55% is expected in the next year compared to the current price of 6.01.
ZURA Ownership
ZURA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 394.886B | ||
| AMGN | AMGEN INC | 17.06 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.1 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.99 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 13.22 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.54 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ZURA
Company Profile
Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 30 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Company Info
ZURA BIO LTD
4225 Executive Square, Suite 600
La Jolla CALIFORNIA US
Employees: 30
Phone: 18582470520
ZURA BIO LTD / ZURA FAQ
Can you describe the business of ZURA BIO LTD?
Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 30 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
What is the stock price of ZURA BIO LTD today?
The current stock price of ZURA is 6.01 USD. The price increased by 6% in the last trading session.
What is the dividend status of ZURA BIO LTD?
ZURA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ZURA stock?
ZURA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about ZURA BIO LTD (ZURA) stock?
13 analysts have analysed ZURA and the average price target is 16.32 USD. This implies a price increase of 171.55% is expected in the next year compared to the current price of 6.01.
What is the market capitalization of ZURA stock?
ZURA BIO LTD (ZURA) has a market capitalization of 390.77M USD. This makes ZURA a Small Cap stock.
What is the outstanding short interest for ZURA BIO LTD?
The outstanding short interest for ZURA BIO LTD (ZURA) is 6.41% of its float.